Jonathan Richard Symonds
ChairSir Jonathan Richard Symonds, CBE, BA, FCA, also known as Jon, has been Director at GSK plc (formerly known as GlaxoSmithKline plc) since September 1, 2019 and serves as its Chair since 2025. He served as Non-Executive Chairman at GSK plc since September 1, 2019 until 2025. Mr. Symonds leads and manages the business of the Board; provides direction and focus; ensures clear structure for effective operation of the Board and its Committees; sets Board agenda and ensures sufficient time is allocated to promote effective debate to support sound decision making; ensures the Board receives accurate, timely and clear information; meets with each Non-Executive Director on an annual basis to discuss individual contributions and performance, together with training and development needs; shares peer feedback that is provided as part of the Board evaluation process; meets regularly with all the Non-Executive Directors independently of the Executive Directors; maintains a dialogue with shareholders on the governance of GlaxoSmithKline. He served as Head of Corporate Finance & Strategy at Mesoblast Limited until December 2021. He had been an Adviser to Board and an Adviser to Chief Executive Officer of Mesoblast Limited since January 19, 2018. He serves as an Advisor at Charlbury Animal Health GmbH. Mr. Symonds served as Senior Advisor at GHO Capital Partners LLP. He served as the Chief Financial Officer at Novartis Institutes for BioMedical Research, Inc. since September 1, 2009. He served as Deputy Chief Financial Officer at Novartis Vaccines and Diagnostics, Inc. He joined Mesoblast as an advisor in 2014. Mr. Symonds served as the Chief Financial Officer of Novartis AG from September 2009 to May 1, 2013. He served as a Non-Executive Director of Rubius Therapeutics, Inc. since April 1, 2018 until February 27, 2023. Mr. Symonds served as an Advisor of Novartis AG since May 1, 2013. He was a Partner and Managing Director of Goldman Sachs from 2007 to 2009. Mr. Symonds served as Managing Director at The Goldman Sachs Group Inc. He served as Deputy Chief Financial Officer at Novartis AG. Mr. Symonds was Partner and Managing Director in the Investment Banking Division at Goldman Sachs in the United Kingdom. He served as Chief Financial Officer at AstraZeneca PLC from October 1997 to July 2007 and was responsible for strategy, including mergers & acquisitions, licensing and business development; investor relations; purchasing and information systems. He has served as Group Finance Director at Zeneca. Prior to joining AstraZeneca in 1997, Mr. Symonds was a Partner at KPMG. He joined KPMG in 1980. He served as Group Finance Director at Zeneca. In 1985 Mr. Symonds spent in the US working on a number of projects involving SEC securities registrations. On returning from the US, Mr. Symonds began to specialize in the chemicals and pharmaceuticals sector and in 1991 was seconded to ICI to help the Board with the separation of the chemicals and pharmaceuticals businesses, which ultimately formed Zeneca. Thereafter, he spent working first with Shell in the Hague and then with Hoechst in Frankfurt, advising them on major structural changes and strategic business. He had been Deputy Group Chairman of HSBC Holdings Plc. since August 6, 2018 until February 18, 2020. He has been the Chairman of Proteus Digital Health, Inc. since November 2015. He has also served, since October 2014, as a director of Genomics England plc, a government organization leading a genomics project, serving as Chairman between January 2019 and November 2019. He served as the Chairperson at Innocoll Holdings plc (formerly known as Innocoll AG) from March 16, 2016 to July 24, 2017. Mr. Symonds served as the Chairperson of Supervisory Board at Innocoll AG (formerly Innocoll GmbH) since May 2014 until March 16, 2016. He served as Chairman of the Board of HSBC Bank Plc since April 14, 2014 until August 6, 2018. Mr. Symonds serves as Chairman of the 100 Group of Finance Directors. He serves as Non-Executive Director of Qinetiq Plc. He serves as board member of the Accounting Standards Board and founder of the Oxford University Centre for Business Taxation Research. Mr. Symonds had been an Independent Non-Executive Director of HSBC Holdings plc since April 14, 2014 and had been its Senior Independent Non-Executive Director since April 28, 2017 until February 18, 2020. He serves as a Director of Novartis Venture Funds. Mr. Symonds has been a Director of Proteus Digital Health, Inc. since June 2014. He served as a Director of Non-Executive Diageo PLC from May 1, 2004 to October 16, 2007. Mr. Symonds served as an Executive Director of AstraZeneca PLC from October 1, 1997 to July 2007 with overall responsibility for Information Services. He served as Director of Qinetiq Group Plc until June 30, 2004. He was a Member at European Round Table for Industry. He is a Member of the Accounting Standards Board's Urgent Issues Task Force and is joint Chairman of the Business Tax Forum. He qualified as a Chartered Accountant in 1982. He has extensive international financial and governance experience. He was awarded a Commander of the British Empire (CBE) for service to industry in the 2007 New Year's honors list. Mr. Symonds holds a BA with a first class degree in business finance from the University of Hertfordshire, UK, in 1980. He is a Fellow of the Institute of Chartered Accountants in England and Wales. He also received an honorary doctorate.
Positions
- Company NameGSK plcStock CodeGSKPositionChairColleagues
- JBJulie Belita BrownCFO & Executive Director
- JLJesse L. GoodmanScientific & Medical Expert
- LVLuke Victor MielsCEO & Director
- SRShobie RamakrishnanChief Digital & Technology Officer
- TWTony WoodChief Scientific Officer and Head of R&D
- CACharles A. BancroftSenior Independent Non-Executive Director
- WMWendy Mira BeckerIndependent Non-Executive Director
